Alto Neuroscience rises after plans to accelerate depression drug development

Alto Neuroscience

20/10/2025 13:26

** Shares of drug developer Alto Neuroscience ANRO.N rise 8.2% to $6.58 premarket

** Company says it plans to accelerate the development of its experimental drug, ALTO-207, for people with treatment resistant depression

** Treatment-resistant depression is a type of major depressive disorder where symptoms do not improve after trying at least two different antidepressant medications at adequate doses and for sufficient time

** The $50 million private placement announced earlier today supports expanded development of ALTO-207 - ANRO

** Company expects to begin late-stage study by early 2027

** As of last close, stock up 43.7% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))